BioNexus Gene Lab Corp Common stock (BGLC) — Long-term Investment Intensity
BioNexus Gene Lab Corp Common stock (BGLC) has a Long-term Investment Intensity of 3.1% as of September 2025. Long-term investments of $237.76K represent 3.1% of total assets of $7.62 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. See BGLC net assets for net asset value and shareholders' equity analysis.
LT Investment Intensity
Long-term Investments
Total Assets
Country
BioNexus Gene Lab Corp Common stock Long-term Investment Intensity (2018–2024)
This chart shows how BioNexus Gene Lab Corp Common stock's Long-term Investment Intensity has evolved across 7 annual periods from 2018 to 2024. As of September 2025, the intensity stands at 3.1%, reflecting long-term investments of $237.76K against total assets of $7.62 Million USD. Also explore BioNexus Gene Lab Corp Common stock (BGLC) total assets for the complete picture of this company's asset base.
Annual Long-term Investment Intensity for BioNexus Gene Lab Corp Common stock (2018–2024)
The table below presents the year-by-year Long-term Investment Intensity for BioNexus Gene Lab Corp Common stock from 2018 to 2024, covering 7 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see market cap of BioNexus Gene Lab Corp Common stock.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2024 | 12.1% | $1.27 Million | $10.43 Million | ▼ -2.8 pp |
| 2023 | 14.9% | $1.70 Million | $11.40 Million | ▲ +1.7 pp |
| 2022 | 13.2% | $1.15 Million | $8.74 Million | ▲ +5.3 pp |
| 2021 | 7.8% | $749.03K | $9.57 Million | ▲ +5.0 pp |
| 2020 | 2.8% | $281.67K | $10.12 Million | ▲ +1.8 pp |
| 2019 | 1.0% | $12.21K | $1.23 Million | ▲ +0.3 pp |
| 2018 | 0.7% | $12.08K | $1.65 Million | — |